Janus kinase inhibitors versus tumour necrosis factor inhibitors in rheumatoid arthritis: meta-analytical comparison of efficacy and safety
Inflammopharmacology (2024) 32:3229–46 doi: 10.1007/s10787-024-01563-3
Kandeel et al. compared JAK inhibitors and TNF inhibitors in RA. JAK inhibitors demonstrated better functional improvement via HAQ-DI but showed insignificant difference in CDAI compared to TNF inhibitors; both classes had similar safety.
The study pooled data from RCTs to examine efficacy using disease activity measures such as the HAQ-DI and CDAI. It also investigated safety outcomes, focusing on thromboembolism and malignancies.
